WEBSITE BSE:544165 NSE: SHIVAM Inc. Year: 2010 Industry: Chemicals My Bucket: Add Stock
Last updated: 11:30
Shivam Chemicals Limited is in the chemical sector particularly in the production and distribution of Hydrated Lime (Calcium Hydroxide) and various other products. Incorporated in October 2010, Shivam Chemicals has made significant strides in supplying over 250,000 metric tons of various products, including Poultry feed supplement (MBM), Di-Calcium Phosphate (Feed Grade), Magnesium Oxide, Limestone Powder, and more. Company’s promoters like Sanjiv Girdharlal Vasant, Soham Sanjiv Vasant, and Shivam Sanjiv Vasant, have been instrumental in...Read More
Shivam Chemicals Limited is in the chemical sector particularly in the production and distribution of Hydrated Lime (Calcium Hydroxide) and various other products. Incorporated in October 2010, Shivam Chemicals has made significant strides in supplying over 250,000 metric tons of various products, including Poultry feed supplement (MBM), Di-Calcium Phosphate (Feed Grade), Magnesium Oxide, Limestone Powder, and more. Company’s promoters like Sanjiv Girdharlal Vasant, Soham Sanjiv Vasant, and Shivam Sanjiv Vasant, have been instrumental in guiding the company. Their leadership has seen the company successfully supply an impressive quantity of products with a cumulative value exceeding INR 7,500 million.The company operates with a consolidated workforce of 25 employees, inclusive of 12 contract laborers sourced from its subsidiary company, Shivam Chemicals and Minerals Private Limited. This subsidiary, situated in Dahej, Gujarat, boasts a manufacturing capacity of 60,000 MT and is primarily engaged in producing Hydrated Lime (Calcium Hydroxide) products. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹192 Cr.
Stock P/E 91.6
P/B 5.4
Current Price ₹112.9
Book Value ₹ 20.9
Face Value 10
52W High ₹130.4
Dividend Yield 0%
52W Low ₹ 55
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 157 | 147 | 224 | |
| Other Income | 0 | 0 | 1 | |
| Total Income | 157 | 147 | 226 | |
| Total Expenditure | 151 | 143 | 220 | |
| Operating Profit | 6 | 4 | 6 | |
| Interest | 0 | 1 | 2 | |
| Depreciation | 0 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 5 | 2 | 3 | |
| Provision for Tax | 1 | 1 | 1 | |
| Profit After Tax | 4 | 1 | 2 | |
| Adjustments | 0 | 0 | 0 | |
| Profit After Adjustments | 4 | 1 | 2 | |
| Adjusted Earnings Per Share | 3 | 1 | 1.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 52% | 0% | 0% | 0% |
| Operating Profit CAGR | 50% | 0% | 0% | 0% |
| PAT CAGR | 100% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 88% | NA% | NA% | NA% |
| ROE Average | 8% | 15% | 15% | 15% |
| ROCE Average | 11% | 14% | 14% | 14% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 14 | 15 | 35 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 7 | 5 | 4 |
| Other Non-Current Liabilities | -0 | 0 | 0 |
| Total Current Liabilities | 11 | 21 | 19 |
| Total Liabilities | 31 | 41 | 58 |
| Fixed Assets | 4 | 15 | 16 |
| Other Non-Current Assets | 10 | 0 | 0 |
| Total Current Assets | 17 | 25 | 43 |
| Total Assets | 31 | 41 | 58 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 9 | 5 | -15 |
| Cash Flow from Investing Activities | -14 | -2 | -1 |
| Cash Flow from Financing Activities | 5 | -3 | 15 |
| Net Cash Inflow / Outflow | 0 | -0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 3.01 | 0.97 | 1.23 |
| CEPS(Rs) | 3.08 | 1.9 | 1.99 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 11.17 | 12.15 | 20.86 |
| Core EBITDA Margin(%) | 3.24 | 2.44 | 2.04 |
| EBIT Margin(%) | 3.5 | 1.92 | 2.11 |
| Pre Tax Margin(%) | 3.25 | 1.39 | 1.35 |
| PAT Margin (%) | 2.38 | 0.82 | 0.93 |
| Cash Profit Margin (%) | 2.44 | 1.6 | 1.51 |
| ROA(%) | 11.94 | 3.34 | 4.21 |
| ROE(%) | 26.92 | 8.34 | 8.29 |
| ROCE(%) | 20.01 | 9.44 | 11.39 |
| Receivable days | 28.16 | 37.83 | 35.23 |
| Inventory Days | 0 | 1.33 | 4.15 |
| Payable days | 5.24 | 13.36 | 12.13 |
| PER(x) | 0 | 0 | 57.16 |
| Price/Book(x) | 0 | 0 | 3.38 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.09 | 0.2 | 0.6 |
| EV/Core EBITDA(x) | 2.44 | 7.46 | 22.36 |
| Net Sales Growth(%) | 0 | -6.37 | 52.95 |
| EBIT Growth(%) | 0 | -48.77 | 68.4 |
| PAT Growth(%) | 0 | -67.66 | 73.48 |
| EPS Growth(%) | 0 | -67.65 | 26.63 |
| Debt/Equity(x) | 0.98 | 1.13 | 0.44 |
| Current Ratio(x) | 1.58 | 1.22 | 2.26 |
| Quick Ratio(x) | 1.58 | 1.19 | 2.02 |
| Interest Cover(x) | 13.91 | 3.67 | 2.79 |
| Total Debt/Mcap(x) | 0 | 0 | 0.13 |
| # | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 73 | 73 | 73 | 73 | 73 | 73 | 73 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 1.48 |
| DII | 1.36 | 0 | 4.89 | 5.65 | 4.72 | 2.83 | 3.19 |
| Public | 25.64 | 27 | 22.11 | 21.35 | 22.29 | 24.18 | 22.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 |
| DII | 0.02 | 0 | 0.08 | 0.1 | 0.08 | 0.05 | 0.05 |
| Public | 0.44 | 0.46 | 0.38 | 0.36 | 0.38 | 0.41 | 0.38 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
